Bruce Neal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2629376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	6.3	9,397
2	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2560-2572.	13.9	6,447
3	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 644-657.	13.9	5,629
4	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	1.2	4,468
5	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
6	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
7	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
8	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	1.2	2,705
9	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, The, 2003, 362, 1527-1535.	6.3	2,300
10	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
11	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	6.3	2,087
12	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet, The, 2000, 356, 1955-1964.	6.3	1,559
13	CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. New England Journal of Medicine, 2016, 375, 919-931.	13.9	1,544
14	Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet, The, 2015, 385, 1975-1982.	6.3	1,522
15	Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA - Journal of the American Medical Association, 2017, 317, 165.	3.8	1,492
16	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, The, 2016, 388, 2532-2561.	6.3	1,399
17	Severe Hypoglycemia and Risks of Vascular Events and Death. New England Journal of Medicine, 2010, 363, 1410-1418.	13.9	1,279
18	Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. New England Journal of Medicine, 2013, 368, 2355-2365.	13.9	1,269

#	Article	IF	CITATIONS
19	Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet, The, 2013, 381, 670-679.	6.3	1,248
20	Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet, The, 2016, 387, 251-272.	6.3	1,121
21	Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52, 2288-2298.	2.9	1,033
22	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet, The, 2016, 387, 435-443.	6.3	792
23	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, The, 2010, 375, 1875-1884.	6.3	788
24	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 1813-1821.	3.0	787
25	Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease. Archives of Internal Medicine, 2003, 163, 1069.	4.3	780
26	Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurology, The, 2008, 7, 391-399.	4.9	732
27	Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. Archives of Internal Medicine, 2005, 165, 1410.	4.3	710
28	A Systematic Review of the Impact of Adherence on the Effectiveness of e-Therapies. Journal of Medical Internet Research, 2011, 13, e52.	2.1	696
29	Blood Pressure Lowering in Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2015, 313, 603.	3.8	673
30	SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2019, 7, 845-854.	5.5	595
31	The global burden of diabetes and its complications: an emerging pandemic. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, s3-s8.	3.1	551
32	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2014, 371, 1392-1406.	13.9	520
33	Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet, The, 2014, 384, 591-598.	6.3	510
34	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 691-704.	5.5	460
35	Effects of Blood Pressure Lowering on Cerebral White Matter Hyperintensities in Patients With Stroke. Circulation, 2005, 112, 1644-1650.	1.6	422
36	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	6.3	414

#	Article	IF	CITATIONS
37	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
38	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation, 2018, 137, 323-334.	1.6	393
39	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Medicine, 2012, 9, e1001293.	3.9	389
40	Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2009, 373, 1009-1015.	6.3	384
41	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 411-419.	5.5	384
42	Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation, 2018, 138, 458-468.	1.6	370
43	Salt Reduction Initiatives around the World – A Systematic Review of Progress towards the Global Target. PLoS ONE, 2015, 10, e0130247.	1.1	338
44	Effect of Salt Substitution on Cardiovascular Events and Death. New England Journal of Medicine, 2021, 385, 1067-1077.	13.9	321
45	Association of Mean Platelet Volume With Risk of Stroke Among 3134 Individuals With History of Cerebrovascular Disease. Stroke, 2004, 35, 622-626.	1.0	312
46	Psychosocial Factors and Risk of Hypertension. JAMA - Journal of the American Medical Association, 2003, 290, 2138.	3.8	310
47	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.	1.2	290
48	Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea. JAMA - Journal of the American Medical Association, 2017, 318, 156.	3.8	287
49	Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. Journal of Hypertension, 2006, 24, 1201-1208.	0.3	262
50	Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia, 2012, 55, 636-643.	2.9	262
51	Salt reduction initiatives around the world. Journal of Hypertension, 2011, 29, 1043-1050.	0.3	257
52	Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2009, 20, 883-892.	3.0	245
53	Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical History. Stroke, 2004, 35, 116-121.	1.0	243
54	Chronic diseases now a leading cause of death in rural India—mortality data from the Andhra Pradesh Rural Health Initiative. International Journal of Epidemiology, 2006, 35, 1522-1529.	0.9	238

#	Article	IF	CITATIONS
55	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. Diabetes Care, 2009, 32, 2068-2074.	4.3	230
56	A one-quarter reduction in the salt content of bread can be made without detection. European Journal of Clinical Nutrition, 2003, 57, 616-620.	1.3	227
57	Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal, 2008, 29, 2669-2680.	1.0	225
58	Effects of Blood Pressure Reduction in Mild Hypertension. Annals of Internal Medicine, 2015, 162, 184-191.	2.0	219
59	Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ, The, 2020, 368, m315.	3.0	218
60	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
61	Midlife Body Mass Index and Hospitalization and Mortality in Older Age. JAMA - Journal of the American Medical Association, 2006, 295, 190.	3.8	209
62	Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2014, 311, 1515.	3.8	206
63	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation, 2016, 134, 1637-1650.	1.6	205
64	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation, 2018, 138, 1537-1550.	1.6	200
65	Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 403-411.	4.3	196
66	Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2009, 52, 2328-2336.	2.9	195
67	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	1.4	194
68	Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurology, The, 2014, 13, 364-373.	4.9	193
69	Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 1237-1250.	2.2	190
70	The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension, 2011, 29, 4-16.	0.3	189
71	Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Circulation, 2013, 128, 1325-1334.	1.6	189
72	BMI and Healthâ€Related Quality of Life in Adults 65 Years and Older. Obesity, 2004, 12, 69-76.	4.0	188

#	Article	IF	CITATIONS
73	Effects of Perindopril-Based Lowering of Blood Pressure on Intracerebral Hemorrhage Related to Amyloid Angiopathy. Stroke, 2010, 41, 394-396.	1.0	188
74	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 2097-2099.	13.9	188
75	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care, 2016, 39, 694-700.	4.3	184
76	Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ: British Medical Journal, 2006, 333, 1044.	2.4	177
77	A systematic survey of the sodium contents of processed foods. American Journal of Clinical Nutrition, 2010, 91, 413-420.	2.2	176
78	Blood Pressure Differences Between Northern and Southern Chinese: Role of Dietary Factors. Hypertension, 2004, 43, 1332-1337.	1.3	175
79	Omega 3 Fatty Acids and Cardiovascular Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 808-818.	0.9	175
80	FoodSwitch: A Mobile Phone App to Enable Consumers to Make Healthier Food Choices and Crowdsourcing of National Food Composition Data. JMIR MHealth and UHealth, 2014, 2, e37.	1.8	173
81	Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia, 2001, 44, 1118-1120.	2.9	163
82	Sodiumâ€Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e014908.	1.6	161
83	The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis. Progress in Cardiovascular Diseases, 2020, 63, 518-524.	1.6	159
84	Rethinking the Dose-Response Relationship Between Usage and Outcome in an Online Intervention for Depression: Randomized Controlled Trial. Journal of Medical Internet Research, 2013, 15, e231.	2.1	152
85	Sodium content of processed foods in the United Kingdom: analysis of 44,000 foods purchased by 21,000 households. American Journal of Clinical Nutrition, 2011, 93, 594-600.	2.2	151
86	International collaborative project to compare and monitor the nutritional composition of processed foods. European Journal of Preventive Cardiology, 2012, 19, 1326-1332.	0.8	149
87	Effects of Fibrates in Kidney Disease. Journal of the American College of Cardiology, 2012, 60, 2061-2071.	1.2	148
88	Population Health Metrics Research Consortium gold standard verbal autopsy validation study: design, implementation, and development of analysis datasets. Population Health Metrics, 2011, 9, 27.	1.3	147
89	Effects of the Mediterranean Diet on Cardiovascular Outcomes—A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0159252.	1.1	145
90	Associations of Proinflammatory Cytokines With the Risk of Recurrent Stroke. Stroke, 2008, 39, 2226-2230.	1.0	142

#	Article	IF	CITATIONS
91	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (<scp>CANVASâ€R</scp>): A randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 387-393.	2.2	139
92	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. European Journal of Preventive Cardiology, 2015, 22, 920-930.	0.8	136
93	Effects of an Angiotensin-converting Enzyme Inhibitor–based Regimen on Pneumonia Risk. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1041-1045.	2.5	133
94	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, The, 2021, 398, 1053-1064.	6.3	133
95	Using verbal autopsy to measure causes of death: the comparative performance of existing methods. BMC Medicine, 2014, 12, 5.	2.3	130
96	The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition. Hypertension, 2003, 42, 297-303.	1.3	129
97	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 393-398.	3.1	127
98	Are gluten-free foods healthier than non-gluten-free foods? An evaluation of supermarket products in Australia. British Journal of Nutrition, 2015, 114, 448-454.	1.2	125
99	Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke. Stroke, 2005, 36, 2143-2147.	1.0	123
100	A Cluster-Randomized, Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (SimCard Trial) in Rural Tibet, China, and Haryana, India. Circulation, 2015, 132, 815-824.	1.6	122
101	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation, 2019, 139, 2591-2593.	1.6	121
102	A Systematic Review of the Sources of Dietary Salt Around the World. Advances in Nutrition, 2020, 11, 677-686.	2.9	121
103	Incidence of heterotopic bone formation after major hip surgery. ANZ Journal of Surgery, 2002, 72, 808-821.	0.3	118
104	Blood pressure lowering and cardiovascular risk – Authors' reply. Lancet, The, 2014, 384, 1746-1747.	6.3	118
105	A Systematic Review of Salt Reduction Initiatives Around the World: A Midterm Evaluation of Progress Towards the 2025 Global Non-Communicable Diseases Salt Reduction Target. Advances in Nutrition, 2021, 12, 1768-1780.	2.9	116
106	Mean population salt intake estimated from 24-h urine samples and spot urine samples: a systematic review and meta-analysis. International Journal of Epidemiology, 2016, 45, 239-250.	0.9	114
107	An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ("Polypillâ€) in People with Raised Cardiovascular Risk. PLoS ONE, 2011, 6, e19857.	1.1	114
108	The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia, 2010, 53, 821-831.	2.9	112

#	Article	IF	CITATIONS
109	Do we need to adjudicate major clinical events?. Clinical Trials, 2008, 5, 56-60.	0.7	111
110	The Second (Main) Phase of an Open, Randomised, Multicentre Study to Investigate the Effectiveness of an Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (Interact2). International Journal of Stroke, 2010, 5, 110-116.	2.9	110
111	Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 312-319.	3.1	108
112	Front-of-pack nutrition labelling to promote healthier diets: current practice and opportunities to strengthen regulation worldwide. BMJ Global Health, 2019, 4, e001882.	2.0	108
113	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	3.0	106
114	Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage. Stroke, 2016, 47, 682-688.	1.0	103
115	Effectiveness of fixed dose combination medication (â€~polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. International Journal of Cardiology, 2016, 205, 147-156.	0.8	103
116	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet, The, 2017, 389, 1035-1042.	6.3	102
117	Oral Disease in Relation to Future Risk of Dementia and Cognitive Decline: Prospective Cohort Study Based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (Advance) Trial. European Psychiatry, 2013, 28, 49-52.	0.1	101
118	Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. Lancet, The, 2018, 391, 1224-1236.	6.3	101
119	Perindopril-Based Blood Pressure–Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. Stroke, 2005, 36, 2164-2169.	1.0	100
120	The International Consortium for Quality Research on Dietary Sodium/Salt (TRUE) position statement on the use of 24â€hour, spot, and short duration (<24Âhours) timed urine collections to assess dietary sodium intake. Journal of Clinical Hypertension, 2019, 21, 700-709.	1.0	100
121	A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthopaedica, 2000, 71, 122-128.	1.4	99
122	The Prevalence and Management of Diabetes in Thai Adults: The International Collaborative Study of Cardiovascular Disease in Asia. Diabetes Care, 2003, 26, 2758-2763.	4.3	99
123	The Prevalence and Management of Diabetes in Rural India. Diabetes Care, 2006, 29, 1717-1718.	4.3	98
124	Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 87-95.	0.9	98
125	Management of NCD in Low- and Middle-Income Countries. Global Heart, 2014, 9, 431.	0.9	98
126	Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering. Journal of the American Society of Nephrology: JASN, 2007, 18, 2766-2772.	3.0	97

#	Article	IF	CITATIONS
127	Internet-Delivered Cognitive Behavioural Therapy for Adults with Mild to Moderate Depression and High Cardiovascular Disease Risks: A Randomised Attention-Controlled Trial. PLoS ONE, 2013, 8, e59139.	1.1	97
128	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
129	Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Global Heart, 2016, 11, 47.	0.9	95
130	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. Circulation, 2020, 141, 407-410.	1.6	95
131	Erectile Dysfunction and Later Cardiovascular Disease in Men With Type 2 Diabetes. Journal of the American College of Cardiology, 2010, 56, 1908-1913.	1.2	94
132	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia, 2019, 62, 926-938.	2.9	94
133	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2019, 30, 2229-2242.	3.0	93
134	Mediators of the Effects of Canagliflozin on HeartÂFailure in Patients With Type 2 Diabetes. JACC: Heart Failure, 2020, 8, 57-66.	1.9	93
135	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	2.6	93
136	Optimizing the analysis strategy for the <scp>CANVAS</scp> Program: A prespecified plan for the integrated analyses of the <scp>CANVAS</scp> and <scp>CANVASâ€R</scp> trials. Diabetes, Obesity and Metabolism, 2017, 19, 926-935.	2.2	89
137	Significant lipid, adiposity and metabolic abnormalities amongst 4535 Indians from a developing region of rural Andhra Pradesh. Atherosclerosis, 2008, 196, 943-952.	0.4	88
138	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	2.2	87
139	Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 2010, 31, 2888-2896.	1.0	85
140	High prevalence of chronic kidney disease in Thailand. Kidney International, 2008, 73, 473-479.	2.6	83
141	Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ: British Medical Journal, 2006, 333, 519.	2.4	82
142	Improving performance of the Tariff Method for assigning causes of death to verbal autopsies. BMC Medicine, 2015, 13, 291.	2.3	80
143	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	1.0	80
144	The Relationship Between Alcohol Consumption and Vascular Complications and Mortality in Individuals With Type 2 Diabetes. Diabetes Care, 2014, 37, 1353-1359.	4.3	79

#	Article	IF	CITATIONS
145	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1796-1803.	4.3	79
146	The Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS). Journal of the American College of Cardiology, 2012, 59, 1188-1196.	1.2	78
147	Effects of interpretive nutrition labels on consumer food purchases: the Starlight randomized controlled trial. American Journal of Clinical Nutrition, 2017, 105, 695-704.	2.2	78
148	Effects of Different Types of Front-of-Pack Labelling Information on the Healthiness of Food Purchases—A Randomised Controlled Trial. Nutrients, 2017, 9, 1284.	1.7	78
149	Cardiovascular disease and risk factors among 345 adults in rural India—the Andhra Pradesh Rural Health Initiative. International Journal of Cardiology, 2007, 116, 180-185.	0.8	76
150	Education, 15-Year Risk Factor Progression, and Coronary Artery Calcium in Young Adulthood and Early Middle Age. JAMA - Journal of the American Medical Association, 2006, 295, 1793.	3.8	76
151	Lower Treatment Blood Pressure Is Associated With Greatest Reduction in Hematoma Growth After Acute Intracerebral Hemorrhage. Hypertension, 2010, 56, 852-858.	1.3	75
152	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 82-91.	2.2	74
153	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet, The, 2021, 398, 1043-1052.	6.3	74
154	Salt intake assessed by 24â€h urinary sodium excretion in a random and opportunistic sample in Australia. BMJ Open, 2014, 4, e003720.	0.8	73
155	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 903-914.	5.5	73
156	Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial. Blood Pressure, 2004, 13, 7-13.	0.7	72
157	Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. , 2004, , CD001160.		72
158	Blood Pressure Variables and Cardiovascular Risk. Hypertension, 2009, 54, 399-404.	1.3	72
159	Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease. Circulation, 2005, 112, 110-116.	1.6	71
160	Prevention, management, and rehabilitation of stroke in low- and middle-income countries. ENeurologicalSci, 2016, 2, 21-30.	0.5	71
161	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. Diabetes Research and Clinical Practice, 2018, 140, 118-128.	1.1	71
162	Nutrient content of products served by leading Australian fast food chains. Appetite, 2010, 55, 484-489.	1.8	70

#	Article	IF	CITATIONS
163	Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes and Vascular Disease Research, 2012, 9, 117-123.	0.9	70
164	A shortened verbal autopsy instrument for use in routine mortality surveillance systems. BMC Medicine, 2015, 13, 302.	2.3	70
165	Twelve-year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the Electricity Generating Authority of Thailand Study. International Journal of Epidemiology, 2003, 32, 461-468.	0.9	69
166	Monitoring the levels of important nutrients in the food supply. Obesity Reviews, 2013, 14, 49-58.	3.1	69
167	An Evaluation of the Effects of the Australian Food and Health Dialogue Targets on the Sodium Content of Bread, Breakfast Cereals and Processed Meats. Nutrients, 2014, 6, 3802-3817.	1.7	69
168	Do Health Claims and Front-of-Pack Labels Lead to a Positivity Bias in Unhealthy Foods?. Nutrients, 2016, 8, 787.	1.7	69
169	Designing a Healthy Food Partnership: lessons from the Australian Food and Health Dialogue. BMC Public Health, 2016, 16, 651.	1.2	69
170	Percentage of ingested sodium excreted in 24â€hour urine collections: A systematic review and metaâ€analysis. Journal of Clinical Hypertension, 2018, 20, 1220-1229.	1.0	69
171	Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney International, 2020, 98, 769-777.	2.6	69
172	A salt-reduction smartphone app supports lower-salt food purchases for people with cardiovascular disease: Findings from the SaltSwitch randomised controlled trial. European Journal of Preventive Cardiology, 2017, 24, 1435-1444.	0.8	68
173	Estimated population wide benefits and risks in China of lowering sodium through potassium enriched salt substitution: modelling study. BMJ, The, 2020, 369, m824.	3.0	68
174	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	3.9	67
175	The variability of reported salt levels in fast foods across six countries: opportunities for salt reduction. Cmaj, 2012, 184, 1023-1028.	0.9	66
176	The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 295-303.	4.3	65
177	The impact of interpretive and reductive front-of-pack labels on food choice and willingness to pay. International Journal of Behavioral Nutrition and Physical Activity, 2017, 14, 171.	2.0	64
178	Socio-economic distribution of cardiovascular risk factors and knowledge in rural India. International Journal of Epidemiology, 2012, 41, 1302-1314.	0.9	63
179	Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)—A large-scale cluster randomized controlled trial. American Heart Journal, 2017, 188, 109-117.	1.2	63
180	The effects of a reduced-sodium, high-potassium salt substitute on food taste and acceptability in rural northern China. British Journal of Nutrition, 2009, 101, 1088-1093.	1.2	62

#	Article	IF	CITATIONS
181	The Influence on Population Weight Gain and Obesity of the Macronutrient Composition and Energy Density of the Food Supply. Current Obesity Reports, 2015, 4, 1-10.	3.5	62
182	Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes. Diabetes Care, 2015, 38, 1891-1897.	4.3	62
183	Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India. Circulation, 2009, 119, 1950-1955.	1.6	61
184	New evidence relating to the health impact of reducing salt intake. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 617-619.	1.1	61
185	The association of knowledge, attitudes and behaviours related to salt with 24-hour urinary sodium excretion. International Journal of Behavioral Nutrition and Physical Activity, 2014, 11, 47.	2.0	60
186	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
187	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	1.0	60
188	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia, 2019, 62, 1854-1867.	2.9	58
189	The Effects of a Community-Based Sodium Reduction Program in Rural China – A Cluster-Randomized Trial. PLoS ONE, 2016, 11, e0166620.	1.1	57
190	Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 68, 371-380.	2.1	57
191	Healthy Food Prescription Programs and their Impact on Dietary Behavior and Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis. Advances in Nutrition, 2021, 12, 1944-1956.	2.9	57
192	Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ: British Medical Journal, 2009, 338, b1492-b1492.	2.4	56
193	World Heart Federation Roadmap for Hypertension – A 2021 Update. Global Heart, 2021, 16, 63.	0.9	56
194	Is a single definition of the metabolic syndrome appropriate?—A comparative study of the USA and Asia. Atherosclerosis, 2006, 184, 225-232.	0.4	55
195	Salt reduction in China: a state-of-the-art review. Risk Management and Healthcare Policy, 2017, Volume 10, 17-28.	1.2	55
196	Impact of the UK voluntary sodium reduction targets on the sodium content of processed foods from 2006 to 2011: Analysis of household consumer panel data. Preventive Medicine, 2013, 57, 555-560.	1.6	54
197	The Effects on Saturated Fat Purchases of Providing Internet Shoppers with Purchase- Specific Dietary Advice: A Randomised Trial. PLOS Clinical Trials, 2006, 1, e22.	3.5	53
198	Salt consumption by Australian adults: a systematic review and metaâ€analysis. Medical Journal of Australia, 2018, 208, 75-81.	0.8	52

#	Article	IF	CITATIONS
199	Mean population salt consumption in India. Journal of Hypertension, 2017, 35, 3-9.	0.3	51
200	Consumers' responses to health claims in the context of other on-pack nutrition information: a systematic review. Nutrition Reviews, 2017, 75, 260-273.	2.6	51
201	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, 2019, 50, 396-404.	1.0	51
202	Effects of sodiumâ€glucose coâ€ŧransporterâ€2 inhibitors in type 2 diabetes in women versus men. Diabetes, Obesity and Metabolism, 2020, 22, 263-266.	2.2	51
203	Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 2010, 28, 1141-1149.	0.3	50
204	Using a Low-Sodium, High-Potassium Salt Substitute to Reduce Blood Pressure among Tibetans with High Blood Pressure: A Patient-Blinded Randomized Controlled Trial. PLoS ONE, 2014, 9, e110131.	1.1	50
205	Effects of Canagliflozin on Amino-Terminal Pro–B-Type NatriureticÂPeptide. Journal of the American College of Cardiology, 2020, 76, 2076-2085.	1.2	50
206	Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy. Stroke, 2012, 43, 1675-1677.	1.0	49
207	A large-scale cluster randomized trial to determine the effects of community-based dietary sodium reduction—the China Rural Health Initiative Sodium Reduction Study. American Heart Journal, 2013, 166, 815-822.	1.2	49
208	Effects of heterotopic bone formation on outcome after hip arthroplasty. ANZ Journal of Surgery, 2003, 73, 422-426.	0.3	48
209	Changes in the sodium content of bread in Australia and New Zealand between 2007 and 2010: implications for policy. Medical Journal of Australia, 2011, 195, 346-349.	0.8	48
210	The Sodium Content of Processed Foods in South Africa during the Introduction of Mandatory Sodium Limits. Nutrients, 2017, 9, 404.	1.7	48
211	Efficacy and Safety of Quarter-Dose Blood Pressure–Lowering Agents. Hypertension, 2017, 70, 85-93.	1.3	48
212	Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. European Heart Journal, 2005, 26, 1910-1915.	1.0	47
213	Circulating bone morphogenetic protein-7 and transforming growth factor-î²1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney International, 2013, 83, 278-284.	2.6	47
214	Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet, The, 2015, 385, 867-874.	6.3	47
215	A systematic interim assessment of the Australian Government's Food and Health Dialogue. Medical Journal of Australia, 2014, 200, 92-95.	0.8	46
216	Consumer awareness and self-reported behaviours related to salt consumption in Australia. Asia Pacific Journal of Clinical Nutrition, 2010, 19, 550-4.	0.3	46

#	Article	IF	CITATIONS
217	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart, 2019, 105, 42-48.	1.2	45
218	Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia, 2021, 64, 2147-2158.	2.9	45
219	A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS ONE, 2017, 12, e0173600.	1.1	45
220	Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. The Cochrane Library, 2013, 2013, CD001160.	1.5	44
221	No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: A randomized trial of 2,649 patients. Acta Orthopaedica, 2000, 71, 129-134.	1.4	42
222	Earlier Blood Pressure-Lowering and Greater Attenuation of Hematoma Growth in Acute Intracerebral Hemorrhage. Stroke, 2012, 43, 2236-2238.	1.0	42
223	Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro–B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease. Archives of Neurology, 2006, 63, 60.	4.9	41
224	Recalibration of a Framingham risk equation for a rural population in India. Journal of Epidemiology and Community Health, 2009, 63, 379-385.	2.0	41
225	International collaborative study of cardiovascular disease in Asia: design, rationale, and preliminary results. Ethnicity and Disease, 2004, 14, 260-8.	1.0	41
226	Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney International, 2008, 73, 963-970.	2.6	40
227	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQq1	1@ 8 843	144kgBT /Ove
228	Mean Dietary Salt Intake in Urban and Rural Areas in India: A Population Survey of 1395 Persons. Journal of the American Heart Association, 2017, 6, .	1.6	40
229	Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension, 2019, 73, 84-91.	1.3	40
230	<scp>Sodiumâ€glucose coâ€ŧransporterâ€2</scp> inhibitors with and without metformin: A metaâ€analysis of cardiovascular, kidney and mortality outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 382-390.	2.2	40
231	Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease. Hypertension, 2005, 45, 69-74.	1.3	39
232	Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2010, 53, 2320-2327.	2.9	39
233	The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Research and Clinical Practice, 2010, 89, 126-133.	1.1	39
234	Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial. American Heart Journal, 2013, 166, 429-434.e1.	1.2	39

#	Article	IF	CITATIONS
235	Nutrient profile of 23 596 packaged supermarket foods and non-alcoholic beverages in Australia and New Zealand. Public Health Nutrition, 2016, 19, 401-408.	1.1	39
236	Modelled Cost-Effectiveness of a Package Size Cap and a Kilojoule Reduction Intervention to Reduce Energy Intake from Sugar-Sweetened Beverages in Australia. Nutrients, 2017, 9, 983.	1.7	39
237	Uptake of Australia's Health Star Rating System. Nutrients, 2018, 10, 997.	1.7	39
238	The Sleep Apnea cardioVascular Endpoints (SAVE) Trial: Rationale, Ethics, Design, and Progress. Sleep, 2015, 38, 1247-1257.	0.6	38
239	Proposed Nomenclature for Salt Intake and for Reductions in Dietary Salt. Journal of Clinical Hypertension, 2015, 17, 247-251.	1.0	38
240	The relative ability of different front-of-pack labels to assist consumers discriminate between healthy, moderately healthy, and unhealthy foods. Food Quality and Preference, 2017, 59, 109-113.	2.3	38
241	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatology, The, 2019, 1, e220-e228.	2.2	38
242	Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. Diabetes Care, 2020, 43, 1157-1163.	4.3	38
243	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases, 2021, 77, 23-34.e1.	2.1	38
244	Effects of Blood Pressure Lowering on Major Vascular Events Among Patients With Isolated Diastolic Hypertension. Stroke, 2011, 42, 2339-2341.	1.0	37
245	Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean. Journal of Hypertension, 2019, 37, 16-23.	0.3	37
246	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	2.2	37
247	Using mobile technology to support lower-salt food choices for people with cardiovascular disease: protocol for the SaltSwitch randomized controlled trial. BMC Public Health, 2014, 14, 950.	1.2	36
248	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy, 2015, 6, 289-302.	1.2	36
249	The Healthfulness of the US Packaged Food and Beverage Supply: A Cross-Sectional Study. Nutrients, 2019, 11, 1704.	1.7	36
250	Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI—UnitedHealth Global Health Centers of Excellence Program. Global Heart, 2016, 11, 5.	0.9	36
251	Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double-blind, controlled trial. American Journal of Clinical Nutrition, 2021, 114, 185-193.	2.2	36
252	Alcohol consumption and the risk of diabetes by body mass index levels in a cohort of 5,636 Japanese. Diabetes Research and Clinical Practice, 2002, 57, 191-197.	1.1	35

#	Article	IF	CITATIONS
253	Greater adverse effects of cholesterol and diabetes on carotid intima–media thickness in South Asian Indians: Comparison of risk factor-IMT associations in two population-based surveys. Atherosclerosis, 2008, 199, 116-122.	0.4	35
254	Dietary Salt Intake and Discretionary Salt Use in Two General Population Samples in Australia: 2011 and 2014. Nutrients, 2015, 7, 10501-10512.	1.7	35
255	Defining â€~Unhealthy': A Systematic Analysis of Alignment between the Australian Dietary Guidelines and the Health Star Rating System. Nutrients, 2018, 10, 501.	1.7	35
256	The burden of fatal and non-fatal injury in rural India. Injury Prevention, 2008, 14, 232-237.	1.2	34
257	Sampling bias in an internet treatment trial for depression. Translational Psychiatry, 2012, 2, e174-e174.	2.4	34
258	Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. Journal of Hypertension, 2016, 34, 781-787.	0.3	34
259	Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open, 2018, 8, e019672.	0.8	34
260	A comparison of the healthiness of packaged foods and beverages from 12 countries using the Health Star Rating nutrient profiling system, 2013–2018. Obesity Reviews, 2019, 20, 107-115.	3.1	34
261	Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial. PLoS ONE, 2013, 8, e55807.	1.1	34
262	Methodological trends in studies based on verbal autopsies before and after published guidelines. Bulletin of the World Health Organization, 2009, 87, 678-682.	1.5	34
263	Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk. BMC Public Health, 2010, 10, 458.	1.2	33
264	Association between alcohol consumption and diabetic retinopathy and visual acuity—the AdRem Study. Diabetic Medicine, 2010, 27, 1130-1137.	1.2	33
265	A Call for Quality Research on Salt Intake and Health: From the World Hypertension League and Supporting Organizations. Journal of Clinical Hypertension, 2014, 16, 469-471.	1.0	33
266	Comparability of HbA1c and lipids measured with dried blood spot versus venous samples: a systematic review and meta-analysis. BMC Clinical Pathology, 2014, 14, 21.	1.8	33
267	Measuring the Healthiness of the Packaged Food Supply in Australia. Nutrients, 2018, 10, 702.	1.7	33
268	Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension, 2010, 28, 395-400.	0.3	32
269	Impact of Blood Pressure Lowering on Cardiovascular Outcomes in Normal Weight, Overweight, and Obese Individuals. Hypertension, 2010, 55, 1193-1198.	1.3	32
270	Internet-based treatment for older adults with depression and co-morbid cardiovascular disease: protocol for a randomised, double-blind, placebo controlled trial. BMC Psychiatry, 2011, 11, 10.	1.1	32

#	Article	IF	CITATIONS
271	Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World?. Diabetes Care, 2011, 34, 2491-2495.	4.3	32
272	Typical food portion sizes consumed by Australian adults: results from the 2011–12 Australian National Nutrition and Physical Activity Survey. Scientific Reports, 2016, 6, 19596.	1.6	32
273	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	2.6	32
274	Sources of Dietary Salt in North and South India Estimated from 24 Hour Dietary Recall. Nutrients, 2019, 11, 318.	1.7	32
275	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.4	31
276	Effects of a community-based salt reduction program in a regional Australian population. BMC Public Health, 2016, 16, 388.	1.2	31
277	Estimated GFR and the Effect of Intensive Blood Pressure Lowering After Acute Intracerebral Hemorrhage. American Journal of Kidney Diseases, 2016, 68, 94-102.	2.1	31
278	The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.	2.2	31
279	Differences between blood-pressure-lowering drugs. Lancet, The, 2000, 356, 352-353.	6.3	30
280	A randomised trial of the effects of an additional communication strategy on recruitment into a large-scale, multi-centre trial. Contemporary Clinical Trials, 2007, 28, 1-5.	0.8	30
281	Trials in Kidney Disease — Time to EVOLVE. New England Journal of Medicine, 2012, 367, 2541-2542.	13.9	30
282	Tobacco use, smoking quit rates, and socioeconomic patterning among men and women: a cross-sectional survey in rural Andhra Pradesh, India. European Journal of Preventive Cardiology, 2014, 21, 1308-1318.	0.8	30
283	Uptake of Australia's Health Star Rating System 2014–2019. Nutrients, 2020, 12, 1791.	1.7	30
284	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	1.2	30
285	Blood Pressure Lowering for the Secondary Prevention of Myocardial Infarction and Stroke. Hypertension, 1997, 29, 537-538.	1.3	30
286	Multimorbidity matters in low and middle-income countries. Journal of Multimorbidity and Comorbidity, 2022, 12, 263355652211060.	0.8	30
287	Fat distribution is strongly associated with plasma glucose levels and diabetes in Thai adults?the InterASIA study. Diabetologia, 2005, 48, 657-660.	2.9	29
288	Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertension Research, 2009, 32, 282-288.	1.5	29

#	Article	IF	CITATIONS
289	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. International Journal of Cardiology, 2013, 170, 30-35.	0.8	29
290	Announcing "Up to Date in the Science of Sodium― Journal of Clinical Hypertension, 2016, 18, 85-88.	1.0	28
291	Availability, Formulation, Labeling, and Price of Low-sodium Salt Worldwide: Environmental Scan. JMIR Public Health and Surveillance, 2021, 7, e27423.	1.2	28
292	Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. European Heart Journal, 2002, 23, 1509-1515.	1.0	27
293	Effects of the End Point Adjudication Process on the Results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke, 2009, 40, 2111-2115.	1.0	26
294	FoodSwitch and use of crowdsourcing to inform nutrient databases. Journal of Food Composition and Analysis, 2017, 64, 13-17.	1.9	26
295	The development of a national salt reduction strategy for Australia. Asia Pacific Journal of Clinical Nutrition, 2009, 18, 303-9.	0.3	26
296	Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. Journal of Clinical Epidemiology, 2009, 62, 650-659.	2.4	25
297	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor–Based Regimens. Hypertension, 2010, 56, 533-539.	1.3	25
298	The Association of Knowledge and Behaviours Related to Salt with 24-h Urinary Salt Excretion in a Population from North and South India. Nutrients, 2017, 9, 144.	1.7	25
299	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
300	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. Diabetes Care, 2018, 41, 1792-1800.	4.3	25
301	Less salt does not necessarily mean less taste. Lancet, The, 1999, 353, 1332.	6.3	24
302	Comparison of Near-Patient Capillary Glucose Measurement and a Risk Assessment Questionnaire in Screening for Type 2 Diabetes in a High-Risk Population in Rural India. Diabetes Care, 2011, 34, 44-49.	4.3	24
303	Changes in the sodium content of Australian ready meals between 2008 and 2011. Asia Pacific Journal of Clinical Nutrition, 2013, 22, 138-43.	0.3	24
304	The lowering of blood pressure after stroke. Lancet, The, 2001, 358, 1994-1995.	6.3	23
305	Salt Intakes, Knowledge, and Behavior in Samoa: Monitoring Saltâ€Consumption Patterns Through the World Health Organization's Surveillance of Noncommunicable Disease Risk Factors (<scp>STEPS</scp>). Journal of Clinical Hypertension, 2016, 18, 884-891.	1.0	23
306	Spot urine samples compared with 24-h urine samples for estimating changes in urinary sodium and potassium excretion in the China Salt Substitute and Stroke Study. International Journal of Epidemiology, 2018, 47, 1811-1820.	0.9	23

#	Article	IF	CITATIONS
307	Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. American Journal of Kidney Diseases, 2022, 79, 244-256.e1.	2.1	23
308	The impact of voluntary front-of-pack nutrition labelling on packaged food reformulation: A difference-in-differences analysis of the Australasian Health Star Rating scheme. PLoS Medicine, 2020, 17, e1003427.	3.9	23
309	Interested in developing a national programme to reduce dietary salt?. Journal of Human Hypertension, 2011, 25, 705-710.	1.0	22
310	An Update on the Salt Wars—Genuine Controversy, Poor Science, or Vested Interest?. Current Hypertension Reports, 2013, 15, 687-693.	1.5	22
311	A Comparison of the Sodium Content of Supermarket Private-Label and Branded Foods in Australia. Nutrients, 2015, 7, 7027-7041.	1.7	22
312	Estimating population food and nutrient exposure: a comparison of store survey data with household panel food purchases. British Journal of Nutrition, 2016, 115, 1835-1842.	1.2	22
313	The impact of level of education on vascular events and mortality in patients with type 2 diabetes mellitus: Results from the ADVANCE study. Diabetes Research and Clinical Practice, 2017, 127, 212-217.	1.1	22
314	Dietary salt intake in the Australian population. Public Health Nutrition, 2017, 20, 1887-1894.	1.1	22
315	Prospective associations of the original Food Standards Agency nutrient profiling system and three variants with weight gain, overweight and obesity risk: results from the French NutriNet-Santé cohort. British Journal of Nutrition, 2021, 125, 902-914.	1.2	22
316	Verbal autopsy coding: are multiple coders better than one?. Bulletin of the World Health Organization, 2009, 87, 51-57.	1.5	22
317	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal of Human Hypertension, 2023, 37, 428-437.	1.0	22
318	The PROGRESS study. Journal of Hypertension, 1995, 13, 1869.	0.3	21
319	Population impact of a high cardiovascular risk management program delivered by village doctors in rural China: design and rationale of a large, cluster-randomized controlled trial. BMC Public Health, 2014, 14, 345.	1.2	21
320	Estimating population salt intake in India using spot urine samples. Journal of Hypertension, 2017, 35, 2207-2213.	0.3	21
321	Evaluation of Alignment between the Health Claims Nutrient Profiling Scoring Criterion (NPSC) and the Health Star Rating (HSR) Nutrient Profiling Models. Nutrients, 2018, 10, 1065.	1.7	21
322	Estimated 24-Hour Urinary Sodium Excretion and Incident Cardiovascular Disease and Mortality Among 398 628 Individuals in UK Biobank. Hypertension, 2020, 76, 683-691.	1.3	21
323	Sources of dietary sodium and implications for a statewide salt reduction initiative in Victoria, Australia. British Journal of Nutrition, 2020, 123, 1165-1175.	1.2	21
324	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Journal of the American College of Cardiology, 2022, 79, 432-444.	1.2	21

#	Article	IF	CITATIONS
325	Cost-effectiveness of reducing salt intake in the Pacific Islands: protocol for a before and after intervention study. BMC Public Health, 2014, 14, 107.	1.2	20
326	The performance and potential of the Australasian Health Star Rating system: a fourâ€year review using the REâ€AIM framework. Australian and New Zealand Journal of Public Health, 2019, 43, 355-365.	0.8	20
327	Interim effects of salt substitution on urinary electrolytes and blood pressure in the China Salt Substitute and Stroke Study (SSaSS). American Heart Journal, 2020, 221, 136-145.	1.2	20
328	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083.	2.2	20
329	Blood Pressure Lowering for the Prevention of Cognitive Decline in Patients with Cerebrovascular Disease. Clinical and Experimental Hypertension, 1997, 19, 843-855.	0.5	19
330	The world health organization—International society of hypertension blood pressure lowering treatment trialists' collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Current Hypertension Reports, 1999, 1, 346-356.	1.5	19
331	Characteristics of non-fatal fall injuries in rural India. Injury Prevention, 2010, 16, 166-171.	1.2	19
332	Incorporating Added Sugar Improves the Performance of the Health Star Rating Front-of-Pack Labelling System in Australia. Nutrients, 2017, 9, 701.	1.7	19
333	Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 251-259.	2.2	19
334	Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Preventive Cardiology, 2012, 19, 1474-1485.	0.8	18
335	Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 98, 83-90.	1.1	18
336	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia, 2014, 201, 671-673.	0.8	18
337	Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1284-1285.	0.9	18
338	Effects of a nationwide strategy to reduce salt intake in Samoa. Journal of Hypertension, 2018, 36, 188-198.	0.3	18
339	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology, 2020, 318, 126-129.	0.8	18
340	The estimated health impact of sodium reduction through food reformulation in Australia: A modeling study. PLoS Medicine, 2021, 18, e1003806.	3.9	18
341	Determinants of Heterotopic Ossification after Total Hip Replacement Surgery. HIP International, 2009, 19, 41-46.	0.9	17
342	Protocol for developing the evidence base for a national salt reduction programme for India. BMJ Open, 2014, 4, e006629.	0.8	17

#	Article	IF	CITATIONS
343	The Australian Food and Health Dialogue – the implications of the sodium recommendation for pasta sauces. Public Health Nutrition, 2014, 17, 1647-1653.	1.1	17
344	A nutrient profiling assessment of packaged foods using two star-based front-of-pack labels. Public Health Nutrition, 2016, 19, 2165-2174.	1.1	17
345	A randomized controlled trial on rehabilitation through caregiver-delivered nurse-organized service programs for disabled stroke patients in rural china (the RECOVER trial): design and rationale. International Journal of Stroke, 2016, 11, 823-830.	2.9	17
346	A comparison of the Health Star Rating system when used for restaurant fast foods and packaged foods. Appetite, 2017, 117, 1-8.	1.8	17
347	An Evaluation of the Healthiness of the Indian Packaged Food and Beverage Supply. Nutrients, 2017, 9, 1103.	1.7	17
348	Estimating the health benefits and cost-savings of a cap on the size of single serve sugar-sweetened beverages. Preventive Medicine, 2019, 120, 150-156.	1.6	17
349	lodine fortification of foods and condiments, other than salt, for preventing iodine deficiency disorders. The Cochrane Library, 0, , .	1.5	16
350	A cluster-randomized controlled trial to evaluate the effects of a simplified cardiovascular management program in Tibet, China and Haryana, India: study design and rationale. BMC Public Health, 2014, 14, 924.	1.2	16
351	Estimating mean change in population salt intake using spot urine samples. International Journal of Epidemiology, 2016, 46, dyw239.	0.9	16
352	Package size and manufacturer-recommended serving size of sweet beverages: a cross-sectional study across four high-income countries. Public Health Nutrition, 2016, 19, 1008-1016.	1.1	16
353	A randomized trial assessing the effects of health claims on choice of foods in the presence of front-of-pack labels. American Journal of Clinical Nutrition, 2018, 108, 1275-1282.	2.2	16
354	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	1.4	16
355	Association Between Circulating GDFâ€15 and Cardioâ€Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial. Journal of the American Heart Association, 2021, 10, e021661.	1.6	16
356	Rationale and design of the Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): A factorial, cluster-randomized trial of 2 practical cardiovascular disease prevention strategies developed for rural Andhra Pradesh, India. American Heart Journal, 2009, 158, 349-355.	1.2	15
357	Monitoring Adherence to Medication by Measuring Change in Blood Pressure. Hypertension, 2010, 56, 612-616.	1.3	15
358	Effects of interpretive front-of-pack nutrition labels on food purchases: protocol for the Starlight randomised controlled trial. BMC Public Health, 2014, 14, 968.	1.2	15
359	Variability in the reported energy, total fat and saturated fat contents in fast-food products across ten countries. Public Health Nutrition, 2015, 18, 2962-2969.	1.1	15
360	The Science of Salt: A Regularly Updated Systematic Review of the Implementation of Salt Reduction Interventions (June–October 2015). Journal of Clinical Hypertension, 2016, 18, 487-494.	1.0	15

#	Article	IF	CITATIONS
361	Stakeholders' perceptions regarding a salt reduction strategy for India: Findings from qualitative research. PLoS ONE, 2018, 13, e0201707.	1.1	15
362	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology: JASN, 2020, 31, 2446-2456.	3.0	15
363	Influence of sugar label formats on consumer understanding and amount of sugar in food choices: a systematic review and meta-analyses. Nutrition Reviews, 2021, 79, 788-801.	2.6	15
364	Budget impact and cost-effectiveness analyses of the COBRA-BPS multicomponent hypertension management programme in rural communities in Bangladesh, Pakistan, and Sri Lanka. The Lancet Global Health, 2021, 9, e660-e667.	2.9	15
365	Plant sterol-enriched milk tea decreases blood cholesterol concentrations in Chinese adults: a randomised controlled trial. British Journal of Nutrition, 2007, 98, 978-983.	1.2	14
366	Comparability of Patient-reported Health Status. Medical Care, 2011, 49, 962-970.	1.1	14
367	Intensification of medication and glycaemic control among patients with type 2 diabetes–Âthe <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2014, 16, 426-432.	2.2	14
368	High variation in manufacturer-declared serving size of packaged discretionary foods in Australia. British Journal of Nutrition, 2016, 115, 1810-1818.	1.2	14
369	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. European Journal of Preventive Cardiology, 2016, 23, 1393-1400.	0.8	14
370	Five year trends in the serve size, energy, and sodium contents of New Zealand fast foods: 2012 to 2016. Nutrition Journal, 2018, 17, 65.	1.5	14
371	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. Diabetes, Obesity and Metabolism, 2020, 22, 530-539.	2.2	14
372	Seventeen-Year Associations between Diet Quality Defined by the Health Star Rating and Mortality in Australians: The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Current Developments in Nutrition, 2020, 4, nzaa157.	0.1	14
373	Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. American Heart Journal, 2021, 231, 56-67.	1.2	14
374	Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care, 2021, 44, 210-216.	4.3	14
375	Estimating the potential impact of Australia's reformulation programme on households' sodium purchases. BMJ Nutrition, Prevention and Health, 2021, 4, 49-58.	1.9	14
376	Changes in the sodium content of leading Australian fastâ€food products between 2009Âand 2012. Medical Journal of Australia, 2014, 200, 340-344.	0.8	13
377	Drop the Salt! Assessing the impact of a public health advocacy strategy on Australian government policy on salt. Public Health Nutrition, 2014, 17, 212-218.	1.1	13
378	Completeness of nutrient declarations and the average nutritional composition of pre-packaged foods in Beijing, China. Preventive Medicine Reports, 2016, 4, 397-403.	0.8	13

#	Article	IF	CITATIONS
379	The Science of Salt: A Regularly Updated Systematic Review of Salt and Health Outcomes (June and July) Tj ETQq1	1.8.78431	14 rgBT /()\ 13
380	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	2.6	13
381	Salt-Related Knowledge, Attitudes and Behaviors (KABs) among Victorian Adults Following 22-Months of a Consumer Awareness Campaign. Nutrients, 2020, 12, 1216.	1.7	13
382	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. Cardiovascular Research, 2022, 118, 1103-1114.	1.8	13
383	The adaptation, validation, and application of a methodology for estimating the added sugar content of packaged food products when total and added sugar labels are not mandatory. Food Research International, 2021, 144, 110329.	2.9	13
384	Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study. Circulation, 2022, 145, 1534-1541.	1.6	13
385	Dietary Salt Is a Public Health Hazard That Requires Vigorous Attack. Canadian Journal of Cardiology, 2014, 30, 502-506.	0.8	12
386	Sodiumâ€glucose coâ€transporterâ€2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 252-257.	2.2	12
387	Deconstructing the Supermarket: Systematic Ingredient Disaggregation and the Association between Ingredient Usage and Product Health Indicators for 24,229 Australian Foods and Beverages. Nutrients, 2021, 13, 1882.	1.7	12
388	Effects Of Internet-Based Tailored Advice on the Use of Cholesterol-Lowering Interventions: A Randomized Controlled Trial. Journal of Medical Internet Research, 2010, 12, e42.	2.1	12
389	BLOOD PRESSURE LOWERING IN PATIENTS WITH CEREBROVASCULAR DISEASE: RESULTS OF THE PROGRESS (PERINDOPRIL PROTECTION AGAINST RECURRENT STROKE STUDY) PILOT PHASE. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 444-446.	0.9	11
390	A feasibility study on using smartphones to conduct short-version verbal autopsies in rural China. Population Health Metrics, 2016, 14, 31.	1.3	11
391	Can front-of-pack labels influence portion size judgements for unhealthy foods?. Public Health Nutrition, 2018, 21, 2776-2781.	1.1	11
392	Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial. , 2019, 29, 276-284.		11
393	Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a doubleâ€blinded, randomizedâ€controlled trial. Journal of Clinical Hypertension, 2020, 22, 1504-1512.	1.0	11
394	Epidemiology of sudden cardiac death in rural South India - insights from the andhra pradesh rural health initiative. Indian Pacing and Electrophysiology Journal, 2011, 11, 93-102.	0.3	11
395	Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. American Journal of Nephrology, 2022, 53, 21-31.	1.4	11
396	Mechanisms of action of the sodiumâ€glucose cotransporterâ€2 (<scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A <i>post hoc mediation</i> analysis of the <scp>CANVAS</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1950-1956.	2.2	11

#	Article	IF	CITATIONS
397	The PROGRESS trial three years later: time for more action, less distraction. BMJ: British Medical Journal, 2004, 329, 970-971.	2.4	10
398	Prevention of cardiovascular disease in a rural region of India and strategies to address the unmet need. Heart, 2011, 97, 1373-1378.	1.2	10
399	Reducing dietary salt intake and preventing iodine deficiency: towards a common public health agenda. Medical Journal of Australia, 2014, 201, 507-508.	0.8	10
400	Protocol for the implementation and evaluation of a community-based intervention seeking to reduce dietary salt intake in Lithgow, Australia. BMC Public Health, 2014, 14, 357.	1.2	10
401	Labelling completeness and sodium content of packaged foods in India. Public Health Nutrition, 2017, 20, 2839-2846.	1.1	10
402	Impact of salt substitute and stepwise reduction of salt supply on blood pressure in residents in senior residential facilities: Design and rationale of the DECIDE-Salt trial. American Heart Journal, 2020, 226, 198-205.	1.2	10
403	The relative importance of primary food choice factors among different consumer groups: A latent profile analysis. Food Quality and Preference, 2021, 94, 104199.	2.3	10
404	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	2.2	10
405	Ambulatory blood pressure adds little to Framingham Risk Score for the primary prevention of cardiovascular disease in older men: secondary analysis of observational study data. BMJ Open, 2014, 4, e006044-e006044.	0.8	9
406	Rapid Blood-Pressure Lowering in Patients With Acute Intracerebral Hemorrhage. Survey of Anesthesiology, 2014, 58, 24-26.	0.1	9
407	Use of Smartphone for Verbal Autopsy. Asia-Pacific Journal of Public Health, 2016, 28, 601-610.	0.4	9
408	Contribution of major food companies and their products to household dietary sodium purchases in Australia. International Journal of Behavioral Nutrition and Physical Activity, 2020, 17, 81.	2.0	9
409	A Comparison of the Nutritional Qualities of Supermarket's Own and Regular Brands of Bread in Sweden. Nutrients, 2020, 12, 1162.	1.7	9
410	Evaluating the Feasibility and Acceptability of a Mobile Health–Based Female Community Health Volunteer Program for Hypertension Control in Rural Nepal: Cross-Sectional Study. JMIR MHealth and UHealth, 2020, 8, e15419.	1.8	9
411	Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. Journal of Hypertension, 2007, 25, 699-705.	0.3	8
412	Excessive Sodium Intake and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 61, 344-345.	1.2	8
413	Statistical Analysis Plan for the Second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). International Journal of Stroke, 2013, 8, 327-328.	2.9	8
414	CPAP in Obstructive Sleep Apnea. New England Journal of Medicine, 2016, 375, 2301-2303.	13.9	8

#	Article	IF	CITATIONS
415	Does education level affect the efficacy of a community based salt reduction program? - A post-hoc analysis of the China Rural Health Initiative Sodium Reduction Study (CRHI-SRS). BMC Public Health, 2016, 16, 759.	1.2	8
416	The Contribution of Major Food Categories and Companies to Household Purchases of Added Sugar in Australia. Journal of the Academy of Nutrition and Dietetics, 2022, 122, 345-353.e3.	0.4	8
417	Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Diabetes Care, 2022, 45, 1893-1899.	4.3	8
418	White rice and risk of type 2 diabetes. BMJ: British Medical Journal, 2012, 344, e2021-e2021.	2.4	7
419	Replacing the hypertension control paradigm with a strategy of cardiovascular risk reduction. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 17-22.	1.8	7
420	Salt sales survey: a simplified, cost-effective method to evaluate population salt reduction programs—a cluster-randomized trial. Hypertension Research, 2016, 39, 254-259.	1.5	7
421	Wellbeing at work among kitchen workers during organic food conversion in Danish public kitchens: a longitudinal survey. European Journal of Public Health, 2016, 26, 323-328.	0.1	7
422	Protocol for a Randomized Trial Assessing Consumer Evaluations of Pre-Packaged Foods that Systematically Vary by Nutrition Information and Product Attributes. BMC Nutrition, 2017, 3, .	0.6	7
423	Use of Added Sugars Instead of Total Sugars May Improve the Capacity of the Health Star Rating System to Discriminate between Core and Discretionary Foods. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 1921-1930.e11.	0.4	7
424	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2522-2533.	1.8	7
425	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. Journal of Hypertension, 2019, 37, 2216-2224.	0.3	7
426	Excess mortality among patients with severe mental disorders and effects of community-based mental healthcare: a community-based prospective study in Sichuan, China. BJPsych Open, 2021, 7, e84.	0.3	7
427	Barriers and Facilitators to Implementing Reduced-Sodium Salts as a Population-Level Intervention: A Qualitative Study. Nutrients, 2021, 13, 3225.	1.7	7
428	Salt intake and iodine status of women in Samoa. Asia Pacific Journal of Clinical Nutrition, 2016, 25, 142-9.	0.3	7
429	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells, 2021, 10, 2699.	1.8	7
430	Factors Associated With the Use of a Salt Substitute in Rural China. JAMA Network Open, 2021, 4, e2137745.	2.8	7
431	The adherence of packaged food products in Hyderabad, India with nutritional labelling guidelines. Asia Pacific Journal of Clinical Nutrition, 2015, 24, 540-5.	0.3	7
432	Blood Pressure Lowering In Diabetes: A Brief Review Of The Current Evidence And Description Of A New Trial. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1108-1111.	0.9	6

#	Article	IF	CITATIONS
433	Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2002, 3, 270-276.	1.0	6
434	Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 413-418.	3.1	6
435	Effects of Blood Pressure Reduction in Mild Hypertension. Annals of Internal Medicine, 2015, 163, 67.	2.0	6
436	Reducing cardiovascular disease risk in diabetes: a randomised controlled trial of a quality improvement initiative. Medical Journal of Australia, 2017, 206, 436-441.	0.8	6
437	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. International Journal of Cardiology, 2021, 324, 165-172.	0.8	6
438	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	2.2	6
439	Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2707-2715.	2.2	6
440	Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia, 2021, 64, 2402-2414.	2.9	6
441	Projected effects on salt purchases following implementation of a national salt reduction policy in South Africa. Public Health Nutrition, 2021, 24, 4614-4621.	1.1	6
442	Low dietary sodium in heart failure: a need for scientific rigour. Heart, 2014, 100, e2-e2.	1.2	5
443	Sodium and potassium content of 24 h urinary collections: a comparison between field- and laboratory-based analysers. Public Health Nutrition, 2018, 21, 1036-1042.	1.1	5
444	Changes in sodium levels of processed foods among the International Food and Beverage Association member companies in Australia: 2013–2017. Journal of Food Composition and Analysis, 2020, 87, 103405.	1.9	5
445	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the <scp>CANVAS</scp> Program. Diabetes, Obesity and Metabolism, 2020, 22, 2199-2203.	2.2	5
446	The Effects of a Supermarket-Based Intervention on the Nutritional Quality of Private-Label Foods: A Prospective Study. Nutrients, 2020, 12, 1692.	1.7	5
447	Sodium Reduction: How Big Might the Risks and Benefits Be?. Heart Lung and Circulation, 2021, 30, 180-185.	0.2	5
448	Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program. Endocrinology, Diabetes and Metabolism, 2021, 4, e00247.	1.0	5
449	Health system gaps in cardiovascular disease prevention and management in Nepal. BMC Health Services Research, 2021, 21, 655.	0.9	5
450	OUP accepted manuscript. European Heart Journal, 2022, , .	1.0	5

#	Article	IF	CITATIONS
451	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5
452	Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes. Current Hypertension Reports, 2001, 3, 340-349.	1.5	4
453	Statistical analysis plan for the Sleep Apnea cardioVascular Endpoints study: An international randomised controlled trial to determine whether continuous positive airways pressure treatment for obstructive sleep apnea in patients with CV disease prevents secondary cardiovascular events. International lournal of Stroke, 2016, 11, 148-150.	2.9	4
454	Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China. Global Heart, 2021, 16, 47.	0.9	4
455	Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease. Nutrition Journal, 2021, 20, 3.	1.5	4
456	Reliable Quantification of the Potential for Equations Based on Spot Urine Samples to Estimate Population Salt Intake: Protocol for a Systematic Review and Meta-Analysis. JMIR Research Protocols, 2016, 5, e190.	0.5	4
457	Hypertension Care Coordination and Feasibility of Involving Female Community Health Volunteers in Hypertension Management in Kavre District, Nepal: A Qualitative Study. Global Heart, 2020, 15, 73.	0.9	4
458	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers, 2021, 13, 5527.	1.7	4
459	Developing long-term strategies to reduce excess salt consumption in Nigeria. European Heart Journal, 2022, 43, 1277-1279.	1.0	4
460	Availability, healthiness, and price of packaged and unpackaged foods in India: A cross-sectional study. Nutrition and Health, 2022, 28, 571-579.	0.6	4
461	Effects of different blood-pressure-lowering regimens on major cardiac events. Lancet, The, 2004, 363, 331-332.	6.3	3
462	Quantifying the Importance of Interleukin-6 for Coronary Heart Disease. PLoS Medicine, 2008, 5, e84.	3.9	3
463	Just add a pinch of salt!current directions for the use of salt in recipes in Australian magazines. European Journal of Public Health, 2010, 20, 96-99.	0.1	3
464	Don't spare the salt?. Medical Journal of Australia, 2011, 195, 111-112.	0.8	3
465	Effects on the estimated cause-specific mortality fraction of providing physician reviewers with different formats of verbal autopsy data. Population Health Metrics, 2011, 9, 33.	1.3	3
466	Commentary: The salt wars described but not explained—an invited commentary on â€~Why do we think we know what we know? A metaknowledge analysis of the salt controversy'. International Journal of Epidemiology, 2016, 45, 262-264.	0.9	3
467	Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment) Tj ETQq1 1 0.	784 3.1 ⁄4 rgl	3T /Øverlock
468	Is salt substitution ready for prime time?. Nature Reviews Cardiology, 2020, 17, 325-326.	6.1	3

#	Article	IF	CITATIONS
469	The impact of baseline potassium intake on the dose–response relation between sodium reduction and blood pressure change: systematic review and meta-analysis of randomized trials. Journal of Human Hypertension, 2021, 35, 946-957.	1.0	3
470	Estimating the potential impact of the Australian government's reformulation targets on household sugar purchases. International Journal of Behavioral Nutrition and Physical Activity, 2021, 18, 138.	2.0	3
471	How many Australian deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels?. Nutrition and Dietetics, 2009, 66, 158-163.	0.9	2
472	Not much need for ambulatory blood pressure monitoring. Medical Journal of Australia, 2011, 195, 634-635.	0.8	2
473	Protocol for a cluster-randomised trial to determine the effects of advocacy actions on the salt content of processed foods. BMC Public Health, 2015, 16, 75.	1.2	2
474	Tick tock: time for a change?. Health Promotion Journal of Australia, 2016, 27, 102-104.	0.6	2
475	Implementing the Communication for Behavioral Impact Framework to Reduce Population Salt Consumption. Journal of Nutrition Education and Behavior, 2016, 48, 350-353.e1.	0.3	2
476	Prevalence of dysglycaemia in rural Andhra Pradesh: 2005, 2010, and 2014. Journal of Diabetes, 2016, 8, 816-823.	0.8	2
477	Effects of an Advocacy Trial on Food Industry Salt Reduction Efforts—An Interim Process Evaluation. Nutrients, 2017, 9, 1128.	1.7	2
478	A Mixed Methods Process Evaluation of a Clustered-Randomized Controlled Trial to Determine the Effects of Community-Based Dietary Sodium Reduction in Rural China. Frontiers in Medicine, 2021, 8, 646576.	1.2	2
479	Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS). Journal of Epidemiology and Community Health, 2021, 75, 540-549.	2.0	2
480	Drawing on Strategic Management Approaches to Inform Nutrition Policy Design: An Applied Policy Analysis for Salt Reduction in Packaged Foods. International Journal of Health Policy and Management, 2020, , .	0.5	2
481	Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. International Journal of Cardiology, 2022, 358, 103-109.	0.8	2
482	A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease. Kidney360, 2022, 3, 1599-1602.	0.9	2
483	Physical activity but no cholesterol-lowering for the elderly: probably not. Journal of Hypertension, 2005, 23, 1785-1786.	0.3	1
484	The ADVANCE trial $\hat{a} \in$ "Authors' reply. Lancet, The, 2008, 371, 26.	6.3	1
485	Introduction. American Journal of Hypertension, 2009, 22, 924-924.	1.0	1
486	Blood pressure in dialysis patients—look before we leap – Authors' reply. Lancet, The, 2009, 373, 1945-1946.	6.3	1

#	Article	IF	CITATIONS
487	Effects of fibrates on cardiovascular outcomes – Authors' reply. Lancet, The, 2010, 376, 1051-1052.	6.3	1
488	1118 QUANTIFYING SALT AND POTASSIUM INTAKE IN VICTORIAN ADULTS. Journal of Hypertension, 2012, 30, e327.	0.3	1
489	Telmisartan and hydrochlorothiazide antihypertensive treatment in high sodium intake population. Journal of Hypertension, 2017, 35, 2077-2085.	0.3	1
490	Salt substitution is a promising but unproven intervention for stroke management. American Journal of Clinical Nutrition, 2017, 106, ajcn167767.	2.2	1
491	Do GLP-1 Receptor Agonists Care if You Have Heart Failure?. Circulation, 2019, 140, 1623-1625.	1.6	1
492	A Novel Cardioprotective Therapy That Also Improves Glycemia. JAMA - Journal of the American Medical Association, 2020, 323, 1349.	3.8	1
493	Sodium, Blood Pressure, and the Likely Massive Avoidable Burden of Cardiovascular Disease. Circulation, 2021, 143, 1568-1570.	1.6	1
494	Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS). BMJ Open, 2021, 11, e045929.	0.8	1
495	1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program. Diabetes, 2019, 68, .	0.3	1
496	Health Services Use and Expenditures among Middle-Aged and Elderly Residents with Hypertension Comorbidity: A Longitudinal Study in Jiangsu Province, China. Chinese Economy, 0, , 1-11.	1.1	1
497	Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension – the SaltSwitch Online Grocery Shopping randomized trial. American Heart Journal, 2022, 252, 70-83.	1.2	1
498	Captopril and conventional treatment had similar effects on cardiovascular morbidity and mortality in patients with primary hypertension. Evidence-based Cardiovascular Medicine, 1999, 3, 74.	0.0	0
499	Diabetes and Vascular Disease: A New International Trial. Asian Cardiovascular and Thoracic Annals, 2003, 11, 180-184.	0.2	0
500	ADVANCE: Blood Pressure Lowering in Diabetes. Journal of Clinical Hypertension, 2009, 11, 108-108.	1.0	0
501	Response to Letter by Kerr and Nasco. Stroke, 2009, 40, .	1.0	0
502	Event Rates in Trials of Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 303, 732.	3.8	0
503	Sanguine about salt reduction. European Journal of Preventive Cardiology, 2012, 19, 1324-1325.	0.8	0
504	Fat chance for physical activity. Population Health Metrics, 2013, 11, 9.	1.3	0

#	Article	IF	CITATIONS
505	Implications of Thiamine Fortification in Cambodian Fish Sauce. JAMA Pediatrics, 2016, 170, e162199.	3.3	0
506	Outcomes of Positive Airway Pressure for Sleep Apnea—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 2043.	3.8	0
507	FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
508	Impact of Salt Substitute and Stepwise Reduction of Salt Supply on Blood Pressure in the Elderly in Nursing Homes (DECIDE-Salt Trial): Protocol and Baseline Characteristics (P13-022-19). Current Developments in Nutrition, 2019, 3, nzz036.P13-022-19.	0.1	0
509	Benefits and Risks of Lowering Sodium Through Potassium-enriched Salt Substitution for Patients with Chronic Kidney Disease in China: A Modelling Study (OR25-05-19). Current Developments in Nutrition, 2019, 3, nzz051.OR25-05-19.	0.1	0
510	Reply. JACC: Heart Failure, 2020, 8, 427.	1.9	0
511	Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT. Journal of Cardiac Failure, 2021, 27, 816-818.	0.7	Ο
512	Meta-analyses of Hypertension Trials. , 2007, , 316-324.		0
513	Meta-Analyses of Hypertension Trials. , 2013, , 244-251.		0
514	26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE. Diabetes, 2020, 69, .	0.3	0
515	Measuring the Healthiness of Ready-to-Eat Child-Targeted Cereals: Evaluation of the FoodSwitch Platform in Sweden. JMIR MHealth and UHealth, 2021, 9, e17780.	1.8	0
516	Title is missing!. , 2020, 17, e1003427.		0
517	Title is missing!. , 2020, 17, e1003427.		0
518	Title is missing!. , 2020, 17, e1003427.		0
519	Title is missing!. , 2020, 17, e1003427.		0
520	Title is missing!. , 2020, 17, e1003427.		0
521	Title is missing!. , 2020, 17, e1003427.		0
522	Title is missing!. , 2020, 17, e1003427.		0

#	Article	IF	CITATIONS
523	Title is missing!. , 2020, 17, e1003427.		0